SCHEMBL16183675

SCHEMBL16183675

CC(Nc1nc(-c2cccnc2)nc2ccc(-c3cccc(F)c3F)cc12)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.63
▸ KMT2A Q03164 3/20 0.63
▸ CLK1 P49759 1/20 0.63
▸ GBA1 P04062 2/20 0.53
▸ LATS1 O95835 3/20 0.52
▸ MAPT P10636 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ PDE5A O76074 3/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ DYRK1A Q13627 2/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ LATS2 Q9NRM7 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183673 0.93 MEN1 (0.67) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183695 0.89 MEN1 (0.52) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183677 0.87 MEN1 (0.69) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183676 0.87 MEN1 (0.69) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183672 0.87 MEN1 (0.71) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183679 0.87 MEN1 (0.68) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183674 0.86 MEN1 (0.77) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL16183766 0.86 MEN1 (0.49) MEN1KMT2ACLK1GBA1LATS1
SCHEMBL14475170 0.85 CYP1A2 (0.59) MEN1KMT2ACLK1GBA1MAPT
SCHEMBL16183678 0.85 MEN1 (0.71) MEN1KMT2ACLK1GBA1LATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MEN1 4814/4885KMT2A 800/4885CLK1 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback